Worldwide, the vast majority of new infections with HIV are acquired through sexual transmission, the major route of transmission to the 16.4 million infected women. Compounds that are developed for topical use to prevent HIV transmission to (microbicides) offer a promising alternative while awaiting the development of an effective vaccine. One such compound, sodium dimandelic acid ether (SAMMA), efficiently inhibits laboratory-adapted as well as primary isolates of HIV in primary cells including CD4+ T-cells as well as PBMC-derived macrophages. It has potent activity against herpes simplex virus, the sexually transmitted disease that is a major co- factor for HIV. Furthermore, it inhibits sperm function and prevents fertilization in the rabbit with no apparent cytotoxicity. The goal of Project I is to define the full scope and mechanism of HIV-1 inhibition of the candidate topical microbicide, SAMMA, as well as rationally designed derivatives and ultimately purified isomers. A major focus will be in utilizing single-cycle infection to carefully determine site of action in the viral life-cycle and primary cells relevant to initial infection (T-cells, macrophages and dendritic cells) as well as primary viral isolates to assess antiviral potential in cell-free and cell-associated infection. Because preliminary work is consistent with SAMMA working on early attachment and entry steps. the ability of the compound to inhibit non-specific and specific interactions between the virus and the cell that occur during this process will be studied. Interactions between the compound and the virus and envelope protein as well as the compound and cells surface components involved in entry will be studied. Lastly, it is anticipated that topical microbicides will be used repeatedly by infected as well as uninfected individuals resulting in chronic exposure of replicating virus to drugs. The potential, therefore, exists under, selective pressure to generate variants relatively resistant to drug. SAMMA-resistant isolates will be derived and characterized to gain a better understanding of the mechanism(s) of inhibition as wells as the potential for generating resistance and cross-resistance to related compounds in vivo. The proposed studies will define the full my inhibitory potential of SAMMA as well as define critical structural/functional relationships in this unique class of compounds.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
1P01HD041763-01
Application #
6553553
Study Section
Special Emphasis Panel (ZHD1)
Project Start
2001-09-26
Project End
2005-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Anderson, Robert A; Feathergill, Kenneth A; Chany 2nd, Calvin J et al. (2009) Nitric oxide-dependent human acrosomal loss induced by PPCM (SAMMA) and by nitric oxide donors occurs by independent pathways: basis for synthesis of an improved contraceptive microbicide. J Androl 30:168-82
Mesquita, Pedro M M; Wilson, Sarah S; Manlow, Philippe et al. (2008) Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol 82:6576-84
Patel, Sarju; Hazrati, Ehsan; Cheshenko, Natalia et al. (2007) Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 196:1394-402
Anderson, Robert A; Feathergill, Kenneth A; Waller, Donald P et al. (2006) SAMMA induces premature human acrosomal loss by Ca2+ signaling dysregulation. J Androl 27:568-77
Chang, Theresa L; Vargas Jr, Jesus; DelPortillo, Armando et al. (2005) Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115:765-73
Scordi-Bello, Irini A; Mosoian, Arevik; He, Cejiang et al. (2005) Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 49:3607-15
Keller, Marla J; Tuyama, Ana; Carlucci, Maria Josefina et al. (2005) Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 55:420-3
John, Minnie; Keller, Marla J; Fam, Ehsan H et al. (2005) Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 192:1731-40
Cheshenko, Natalia; Keller, Marla J; MasCasullo, Veronica et al. (2004) Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 48:2025-36
Keller, M J; Klotman, M E; Herold, B C (2003) Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am J Reprod Immunol 49:279-84

Showing the most recent 10 out of 13 publications